After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

This quarter, analysts are expecting PacBio’s revenue to decline 31.5% year on year to $39.96 million, a reversal from the 113% increase it recorded in the same quarter last year. Adjusted loss is ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

PACB), also known as PacBio, both fell 10%, while Illumina (NASDAQ:ILMN) and Bio-Rad (BIO) shares fell 5% and 4%, respectively. Shares of Qiagen (QGEN) and Bruker (BRKR) slid 3%, with shares of ...